Table 1.

Patient, treatment, and toxicity data for the ten patients who received the recombinant human hsp110-gp100 chaperone complex melanoma vaccine.

Patient	Age	Gender	Stage	Prior Surgery*	Prior Radiation	PriorImmunotherapy	Dose Received	Toxicity Event	Number of Events	Grade of Event†
PT 01	66	F	IV	Yes	No	Yes	30 mcg	Erythematous Skin Rash	1	1
PT 02	79	M	IV	Yes	Yes	Yes	60 mcg	None	0	0
PT 03	74	F	IV	Yes	No	No	90 mcg	None	0	0
PT 04	81	F	IV	No	Yes	Yes	120 mcg	None	0	0
PT 05	72	F	IV	Yes	Yes	Yes	180 mcg	None	0	0
PT 06	36	F	IV	Yes	Yes	Yes	180 mcg	None	0	0
PT 07	46	F	IIIC	Yes	Yes	Yes	180 mcg	Fever + Hyperhidrosis	5 + 1	1
PT 08	85	F	IV	No	Yes	Yes	180 mcg	None	0	0
PT 09	48	M	IV	No	Yes	Yes	180 mcg	None	0	0
PT 10	60	F	IIIC	Yes	Yes	Yes	180 mcg	None	0	0

^*For therapeutic Intent

^†No grade 2 or higher adverse events occurred in the cohort